Drug profile · INN
pyrimethamine
PYRIMETHAMINE
pyrimethamine (PYRIMETHAMINE) is a dihydrofolate reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — pyrimethamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
pyrimethamine (PYRIMETHAMINE) is a dihydrofolate reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Bifunctional dihydrofolate reductase-thymidylate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is pyrimethamine?
pyrimethamine (PYRIMETHAMINE) is a dihydrofolate reductase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pyrimethamine?
PYRIMETHAMINE is a marketed brand name for pyrimethamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pyrimethamine?
pyrimethamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.